The CDC expanded RSV vaccine recommendations to include adults aged 50 and above who have underlying health conditions ...

FDA approves Merck's RSV shot for infants, ramping up competition with Sanofi and AstraZeneca By Annika Kim Constantino, CNBC • Published June 9, 2025 • Updated on June 9, 2025 at 3:15 pm ...

Merck said it plans to make the drug available in the U.S. ahead of the upcoming RSV season. Enflonsia joins a growing arsenal of tools to prevent RSV in infants.

Merck won approval from the U.S. Food and Drug Administration for a shot that protects against RSV, the most common cause of hospitalization among infants, STAT notes.

Merck's shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus, which was in short supply nationwide during the 2023 RSV season due to unprecedented ...